 |
NVS
Pre-Market Movers: $NVO,$FCL,$PCZ,$GSK,$ERTS,$HBC,$DDR,$DB,$GFA,$NVS...more
NVS
Novartis $NVS in-licenses a mid-to-late-stage experimental hepatitis C drug from a private Swiss co. Gains exclusive WW rights,except Japan.
NVS
Monday February 8 2010 MACD Sell Signal $ALXN $BAP $GILD $MCD $ROST $NVS $PETD $PII $LKFN $NTY #economics
NVS
@drpdtapp yes $NVS have Afinitor and $GSK have pazopanib. There are 6 approved in renal cc now
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. $RHHBY $NVS (@mhuckman)
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. Crew tweaking lights now. $RHHBY $NVS
NVS
Allergan’s Looking Real Pretty Right Now http://cnbc.com/id/35238576 $ABT $ACL $AGN $NVS #StockPicks #StockMarket
NVS
RT@MhuckmanRoche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHH
NVS
Roche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHHBY $NVS
NVS
Pfizer Earnings By the Numbers http://cnbc.com/id/35196988 $AMGN $BIIB $GENZ $GILD $MRK $NVS $PFE $WAT #StockMarket
NVS
$NVS $CSBTF Hypertension Market Will Be Constrained Through 2018 by Pipeline Containing Few Novel Emerging Therapies http://bit.ly/c3boXR
NVS
Is Genentech/Roche turning a blind eye to a marketing/PR opportunity for Lucentis/Avastin? Vote in the poll. http://bit.ly/9VSjxq $NVS
NVS
RT @adamfeuerstein: @mhuckman: Kaiser "real-world" study:Avastin = Lucentis for AMD. $NVS $RHHBY Genentech: Only L proven safe,eff
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
RT @mhuckman: Kaiser "real-world" study:Avastin works as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
Novartis AG - NVS Insiders
Novartis, 4619 follower(s), 11 friend(s)Novartis, Company
Description: We provide healthcare solutions that address the evolving needs of patients and societies worldwide.
URL: http://novartis.com
Novartis AG - NVS information
Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division engages in the research, development, manufacture, distribution, and sale of pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; and immunology and infectious diseases. The company?s Vaccines and Diagnostics division offers preventive vaccine treatments and diagnostic tools. It provides influenza, meningococcal, pediatric, and traveler vaccines; and blood testing and molecular diagnostics to prevent the spread of infectious diseases. The company?s Sandoz division offers drugs, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; anti-infectives; protein or biotechnology-based products; and biotech manufacturing to other companies on a contract basis. Its Consumer Health division consists of three business units: over-the-counter medicines (OTC), Animal Health, and CIBA Vision. OTC offers over-the-counter self medications. Animal Health provides veterinary products for farm and companion animals. CIBA Vision manufactures contact lenses and lens care products. Novartis AG has strategic alliance with Intercell AG to develop vaccines; CombinatoRx Incorporated to discover anti-cancer combinations; Ablynx NV for the discovery and development of Nanobody-based therapeutics; and MorphoSys AG. It also has research and development collaboration agreements with EpiStem Holdings Plc; Euroscreen S.A.; Nuevolution A/S; and Locus Pharmaceuticals, Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland....
www.novartis.com
99,834 Employees
Founded in 1895
NOVARTIS AG-ADR (NVS:NYSE)
LAST $54.67 USD
CHANGE TODAY +0.03 0.05%
VOLUME 1.9M
As of 8:04 PM 03/10/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of NOVARTIS AG-ADR (NVS)
|
OPEN
$54.47
|
PREVIOUS CLOSE
$54.64
|
|
|
DAY HIGH
$54.88
|
DAY LOW
$54.45
|
|
|
52 WEEK HIGH
12/3/09 - $56.42
|
52 WEEK LOW
03/11/09 - $33.82
|
|
|
MARKET CAP
144.2B
|
AVERAGE VOLUME 10 D
3.4M
|
|
|
EPS TTM
$3.70
|
SHARES OUTSTANDING
2.6B
|
|
|
EX-DATE
03/2/10
|
P/E TTM
14.8x
|
|
|
DIVIDEND
$1.99
|
DIVIDEND YIELD
3.64%
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Lessons of a $618,616 Death
03/04/2010 5:00 PM ET
Swine Flu: The Pandemic That Wasn't
02/04/2010 5:00 PM ET
The New Man at Novartis
02/04/2010 5:00 PM ET
Why M&A Funds Are Hot
01/21/2010 5:00 PM ET
Key developments for NOVARTIS AG-ADR (NVS)
Novartis AG Reports Earnings Results for Year Ended December 31, 2009
03/9/2010
Novartis AG reported earnings results for year ended December 31, 2009. For the period, the company reported income from continuing$9,922 million and total earnings of $10,797 million as compared to income from continuing$ 9,499 million and total earnings of $9,711 million for the same period last year.
Novartis AG Announces Introduction of Consultative Vote on the Compensation System in the Articles of Incorporation
02/26/2010
Novartis AG announced that shareholders approved the introduction of a consultative vote on the compensation system in the articles of incorporation. Such a vote will be held before every significant change in the compensation system, but at least at every third Annual General Meeting the first such vote will take place at the Annual General Meeting in 2011. The three year cycle for votes allows shareholders to take a longer-term view when examining the sustainability of the compensation system. Sustainable compensation systems are harmonized with multi-year business plans, and only attain their full effect when used unchanged for several years, so they are understood by all employees.
Novartis Seeks Small Acquisitions
02/26/2010
Joe Jimenez, CEO of Novartis AG, said that the firm is likely to seek small acquisitions in the future, not other multibillion-dollar deals like the acquisition of Alcon. The firm will most likely pursue smaller acquisitions to boost its vaccine, generics and consumer health business.
NVS Competitors
| Company | Last | Change |
| Abbott Laboratories | $55.03 USD | +0.23 |
| Bayer AG | €52.13 EUR | -0.28 |
| Pfizer Inc | $17.15 USD | -0.08 |
| Roche Holding AG | SFr.179.10 CHF | +0.40 |
| Sanofi-Aventis SA | €55.95 EUR | -0.18 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | NVS | Industry Range |
| Price/Earnings | 14.8x |
|
| Price/Sales | 2.8x |
|
| Price/Book | 2.2x |
|
| Price/Cash Flow | 17.2x |
|
| TEV/Sales | 2.5x |
|
|
NVS |
||
|
NVS transactions
| Type Date |
Target |
|
Merger/Acquisition
January 4, 2010 |
Alcon Inc. |
|
Merger/Acquisition
January 4, 2010 |
Alcon Inc. |
|
Merger/Acquisition
December 22, 2009 |
Corthera Inc. |
Novartis AG - NVS news
US corp bond sales climb as risk appetite returns
2010-03-11 01:56:21
Keywords: United States of America,U.S. corporate debt,Debt,Investment grade debt,
Quote: Demand is also strong for highly rated companies like Swiss
pharmaceutical giant Novartis (NOVN.VX) (NVS.N). Its subsidiary
Novartis Capital Corp on Tuesday sold the week's largest deal,
a $5 billion offering, increasing it by 25 percent in response
to demand, traders said.(Reporting by Dena Aubin; additional reporting by Tom Ryan;
Editing by Kenneth Barry)......Read article
New Issue-Novartis Capital sells $5 bln in 3 parts
2010-03-10 02:58:08
Keywords: United States of America,Debt,U.S. corporate debt,Terms and conditions - bond issues,Loans,
Quote: New Issue-Novartis Capital sells $5 bln in 3 parts
March 9 (Reuters) - Novartis Capital Corp, a subsidiary of
Novartis AG (NOVN.VX) (NVS.N), on Tuesday sold $5 billion of
senior notes in three parts, said IFR, a Thomson Reuters
service. The notes are guaranteed by Novartis AG.The size of the deal was increased from an originally
planned $4 billion.Goldman Sachs and JP Morgan were the active joint
bookrunning managers for the sale. Bank of America Merrill
Lynch, Barclays Capital, Citigroup and Mo...Read article
Former Peninsula Manager Starts His Own Charity Fund
2010-03-08 02:57:03
Keywords: Peter Gautschi, Peninsula, Studer Trust Myanmar schools
Quote: Other donors include women's group Zonta International, the Asia Business Council and NovartisNVSnewspeople). "When you run a hotel or a business, you have to be efficient," he says. "There was none of it [with Unesco]. There was no expertise. There was no control, and that's what shook me. That cannot be charity."Gautschi has set up a fund so that the trust's work will proceed no matter what happens to him. He is hesitant, however, to lay out any ambitious plans for expansion that could sacrifi...Read article
Cash-Rich Firms Snare Rivals In Flurry Of Deals Private Equity Still Cautious
2010-03-03 02:24:19
Quote: Novartis paid more than $38 billion for the 77% stake it didn't already own in Alcon.Fewer Big Pharma Deals SeenPFENewsRHHBY.obNewsMRKNews) $43 billion takeover of Schering-Plough.Industry watchers expect to see much less action in 2010."The Big Pharma merger wave is over until 2012 or 2013," said Les Funtleyder, analyst at Miller Tabak. "A lot of what happened last year was related to depressed valuations, and they're not so depressed anymore. So things are kind of in a holding pattern right no...Read article
HGS finance chief resigns
2010-03-02 05:47:40
Quote: He had worked for Swiss pharmaceutical Novartis AG before that.Barabe’s resignation comes the week before Human Genome Sciences is scheduled to report fiscal fourth-quarter and full 2009 financial results. The company, which had a breakout year last year with successful lupus drug trials and soaring stock prices, had third-quarter revenue of $18.8 million, with a net loss of $49 million.Last month, Barabe sold more than 80,100 shares of company stock that he had acquired for roughly $293,3...Read article
Cash-Rich Firms Snare Rivals In Flurry Of Deals Private Equity Still Cautious
2010-03-02 05:47:35
Quote: Novartis paid more than $38 billion for the 77% stake it didn't already own in Alcon.Fewer Big Pharma Deals SeenPFENewsRHHBY.obNewsMRKNews) $43 billion takeover of Schering-Plough.Industry watchers expect to see much less action in 2010."The Big Pharma merger wave is over until 2012 or 2013," said Les Funtleyder, analyst at Miller Tabak. "A lot of what happened last year was related to depressed valuations, and they're not so depressed anymore. So things are kind of in a holding pattern right no...Read article
Your Money with Chuck Jaffe: Analyst taps quality stocks and emerging markets
2010-03-02 05:47:34
Keywords: Investing|Stocks, CSCO, Cisco Systems Inc, MSFT, Microsoft Corporation, IBM, International Business Machines, PFE, Pfizer Inc, NVS, Novartis AG, JNJ, Johnson & Johnson, PEP, PepsiCo Inc, KO, Coca-Cola Co, POGRX, PRIMECAP:Odyssy Growth, FCNTX, Fidelity
Quote: He also suggests health-care giants Pfizer Inc./quotes/comstock/13*!pfe/quotes/nls/pfe(PFE17.75,+0.20,+1.14%) and Novartis AG/quotes/comstock/13*!nvs/quotes/nls/nvs(NVS55.52,+0.20,+0.36%), along with Johnson & Johnson/quotes/comstock/13*!jnj/quotes/nls/jnj(JNJ63.39,+0.39,+0.62%), Pepsi Co./quotes/comstock/13*!pep/quotes/nls/pep(PEP63.43,+0.96,+1.54%) and Coca-Cola Co./quotes/comstock/13*!ko/quotes/nls/ko(KO53.27,+0.55,+1.04%).Listen to the full interview with Goldberg: Blue chips, emerging m...Read article
Novartis' Great Weekend
2010-02-23 08:35:26
Keywords: Medicine, Pharmacuticals, Health Care, Drugs, Drug Companies, Hospitals, Health Insurance
Quote: Even as GlaxoSmithkline got slammed with a new Congressional investigation over the safety of the diabetes drug Avandia, Novartis quietly had a good weekend. It snared a fast six-month priority review for both its multiple sclerosis drug and a new use of its leukemia drug Tasigna. And its meningitis vaccine Menveo was approved for use in people ages 11 to 55.
Now comes the harder part--getting the MS drug and the new leukemia drug use approved by the Food and Drug Administration. The MS drug, FT...Read article
DHS extends GenVec vaccine contract
2010-02-22 05:04:37
Quote: will continue to develop vaccines against foot-and-mouth disease for the Department of Homeland Security under a new contract worth as much as $4.5 million.GenVec is developing FMD vaccines based on research done in collaboration with the USDA at the Plumb Island Animal Disease Center, and is basing the research on its adenovector technology.Under the contract, GenVec will research methods to increase the potency and simplify the production process of FMD vaccines.GenVec first began working on F...Read article
European Stocks Gain For Fifth Day
2010-02-22 05:04:36
Quote: Drugmaker Novartis climbed 1.5% in Zurich. Its Tasigna drug was granted priority review by the U.S. Food and Drug Administration for the treatment of adult patients with a form of newly diagnosed leukemia.
French retailer Carrefour fell 2% in Paris after its fiscal-year net profit fell 74%.
Anglo American dropped 1.8% in London after the miner reported a steep drop in profit and declared no dividend for the second year in a row.
Thales tumbled 12% in Paris after the defense and aerospace contr...Read article
Fed Move Subdues Asian Stocks; Nestlé Stirs Europe
2010-02-22 05:04:35
Quote: "This favors sectors like autos, food, health care and technology."
Drugmaker Novartis climbed 1.5%. It said its Tasigna drug has been granted priority review by the U.S. Food and Drug Administration for leukemia treatment.
Ongoing worries about Greece's fiscal woes seemed to be on the back burner, with the Greek ASE Composite index rising 2.4% to 1927.62.
In LONDON, the FTSE 100 rose 0.6% to 5358.17, picking up 4.2% for the week. Shire gained 4.6% after reporting a 23% jump in 2009 net incom...Read article
FDA orders name change for Maalox Total Relief
2010-02-19 03:52:10
Quote: The anti-diarrhea medication is often confused with traditional Maalox, which uses a gentler formula to neutralize stomach acid.Both products are available over-the-counter without a prescription.The FDA said Swiss manufacturer Novartis will rename Maalox Total Relief and change its packaging to avoid confusion. The rebranded product should be available by September."We want companies to consider the potential for name confusion when choosing names for their drugs," said Carol Holquist, FDA's di...Read article
[$$] Novartis to Clear Up Maalox Confusion
2010-02-19 03:52:09
Quote: BY JENNIFER CORBETT DOOREN WASHINGTON—Novartis AG said it will stop selling medicines with different active ingredients under the same Maalox brand name after the Food and Drug Administration warned about potentially harmful consumer confusion. The agency said it has received five reports of "serious medication errors" connected to Maalox mix-ups. Traditional Maalox liquid products such as Maalox Advanced Regular Strength and Maalox Advanced Maximum Strength are antacids. However, Novar...Read article
Does India Want Drug Innovation or Not?
2010-02-19 03:52:07
Quote: Novartis, antiretroviral drug Viread and now Bayer's Nexavar.
Degrading patents has serious side effects. Unauthorized generic copies aren't always as safe as branded products. India already has to deal with a huge fake drug industry. If foreign companies don't think their inventions will be protected, they are less incentivized to invest in research and development. Since new drugs cost roughly $1 billion each to develop and bring to market globally, easy and early copying can be devastating fo...Read article
No Cure For Fake Drugs
2010-02-16 02:22:16
Quote: A trial date hasn't yet been set.
All were fakes with no medicinal value, copies of legitimate medicines made by Novartis AG, Sanofi-Aventis SA, Bristol-Myers Squibb Co., Roche Holding AG and Pfizer Inc.
The bust, which also seized equipment used to make and package fake drugs, stopped one ring's lucrative trade of counterfeits to Iraq, Turkey, Lebanon, Iran and Egypt, according to pharmaceutical-company managers and a Syrian official familiar with the investigation. Pfizer, Bristol-Myers, Novar...Read article
Teva and Novartis reach settlement on Famvir suit
2010-02-16 02:22:16
Keywords: , TEVA, Teva Pharmaceutical Industries Ltd, NVS, Novartis AG
Quote: signed an agreement with Novartis/quotes/comstock/13*!nvs(NVS53.71,0.00,0.00%) to settle a patent lawsuit over Teva's generic version of the Novartis-developed antiviral medication Famvir. Under terms of the settlement, Teva will make a one-time payment to Novartis as well as ongoing royalty fees on U.S. sales of generic Famvir. Israel-based Teva didn't disclose the amount it will pay. Famvir is used to treat herpes and shingles.......Read article
Drug Firms Apply Brand to Generics
2010-02-16 02:22:15
Keywords: Drugs (Pharmaceuticals),Generic and Brand Name Products,Sanofi-Aventis SA,GlaxoSmithKline PLC,Pfizer Inc,Medley Pharmaceuticals,Novartis AG,Mergers Acquisitions and Divestitures,Trademarks and Trade Names
Quote: Viehbacher said, which includes mint-green packaging that is a visible logo on pharmacy shelves.NovartisSandoz, recognized the consumer interest and business opportunity in generic drugs early on.Novartis. “Some competitors said that this was not right to enter a field that was competing with our own.”Now, with organic growth and the acquisition of branded generics like the German maker Hexal, Sandoz is the world’s second-largest purveyor of generic drugs, after Teva.Branded ge...Read article
Alcon says Novartis proposal weak given earnings
2010-02-15 08:03:39
Keywords: , ACL, Alcon Inc, NVS, Novartis AG, NSRG.Y, Nestle S A
Quote: SAN FRANCISCO (MarketWatch) -- An independent director committee of Alcon/quotes/comstock/13*!acl/quotes/nls/acl(ACL157.52,-0.58,-0.37%) said Friday that the company's strong earnings reinforce its belief that Novartis'/quotes/comstock/13*!nvs/quotes/nls/nvs(NVS53.71,-0.15,-0.28%) proposal is "grossly" inadequate. Alcon late Thursday reported that its fourth-quarter profit rose to $1.51 a share from $1.41 a share in the same quarter last year. Revenue increased to $1.72 billion from $1.5 billion...Read article
Alcon Profit Rises as Novartis Takeover Looms
2010-02-15 08:03:38
Keywords: Mergers & Acquisitions, Investment Banking, I PO, I.P.O.s, IPOs, Offerings, Private Equity, Hedge Funds, Venture Capital, Legal, The New York Times, Andrew Ross Sorkin, Andrew Sorkin, DealBook, deal maker, Wall street, wall st., Goldman Sachs, Goldman Sa
Quote: Alcon, the eye-care products maker being acquired by Swiss drug maker Novartis, reported higher fourth-quarter profit on Thursday, helped by double-digit sales increases in the United States. and emerging markets, Reuters reported.
Alcon posted a net profit of $458 million, or $1.51 per share, compared with a profit of $424 million, or $1.41 per share, a year ago.
Thomson Reuters.
Revenue for the quarter rose 14.5 percent to $1.72 billion, exceeding Wall Street estimates of $1.6 billion.
For 201...Read article
Novartis licenses Hepatitis C drug
2010-02-09 03:21:45
Keywords: , NVS, Novartis AG, NOVN, Novartis Ag
Quote: LONDON (MarketWatch) -- Novartis/quotes/comstock/13*!nvs/quotes/nls/nvs(NVS53.08,-0.33,-0.62%)/quotes/comstock/06p!novn(CH:NOVN57.20,0.00,0.00%) said it has licensed Debio 025, or alisporivir, a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease. It's been licensed from Debiopharm Group, an i...Read article